Tracer library / [177Lu]Lu-J591

[177Lu]Lu-J591

Also written as Lu-177-J591; [Lu-177]Lu-J591

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer Dosimetry and biodistribution studies PSMA-directed radioligand therapy

What it is

Compound class: Anti-PSMA monoclonal antibody (J591)
Target / mechanism: Targets prostate-specific membrane antigen (PSMA) PMID 33778927
Clinical application: PSMA-targeted radionuclide therapy in metastatic castration-resistant prostate cancer PMID 33778927
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
2021 · Prostate · Prospective · Phase I/II

Need this precursor?We can point you to suppliers for [177Lu]Lu-J591, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33778927: 'escalating doses of 177Lu-J591'. Stage set/updated at stage 23 from PMID 33778927: 'Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration-resistant prostate cancer (mCRPC).'. | Stage 30 (2026-09-18): Stage was 'investigational'; normalised to 'Clinical research', original wording kept here.